Japanese company profile · 2927

AFC-HD AMS Life Science Co.,Ltd.

English company name recorded in Japan's EDINET filer data.

Original Japanese company name: 株式会社AFC-HDアムスライフサイエンス

Name follows the English name recorded in EDINET filer data. English company name source

FY2024 · fiscal year ended August 2025Latest filing date: 2025-11-26

What does this company do?

What does this company do?

In its FY2024 public filing, AFC-HD AMS Life Science Co.,Ltd. reports Healthcare, Pharmaceuticals, Department Store Business, Food Service, and 1 other reported businesses. The page shows business-level revenue and profit where the source disclosures support comparison.

AFC-HD AMS Life Science Co.,Ltd.'s largest reported business by revenue in FY2024 was Healthcare.

The business with the highest reported segment profit in FY2024 was Healthcare.

FY2024 · fiscal year ended August 2025 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥32.66B ↗
FY2024 · fiscal year ended August 2025
Operating profit
¥2.41B ↗
FY2024 · fiscal year ended August 2025
Comparable margin
7.4% ↗
FY2024 · fiscal year ended August 2025

JGAAP · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
2927
EDINET code
E01064
Corporate number
3080001005054
Listing status
Listed
Industry (EDINET filer classification)
Food products

Location and fiscal year

Headquarters
静岡県静岡市 · As filed in Japanese
Fiscal year end
8month
Latest fiscal year
FY2024
Accounting standard
JGAAP
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
1,008 people (FY2024)
Employees (non-consolidated)
360 people (FY2024)
Capital stock
JPY 2.1 billion (FY2024)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

Revenue leader and profit leader

Healthcare

FY2024 · fiscal year ended August 2025 · Business Sales Operating profit
BusinessSalesShare of company salesOperating profitMargin
Healthcare¥19.04B ↗57.9%57.9%Sales to external customers: ¥18.9B ↗¥2.45B ↗12.9%
Department Store Business¥4.62B ↗14.1%14.1%Sales to external customers: ¥4.61B ↗¥61.8M ↗1.3%
Real estate and construction¥2.71B ↗8.2%8.2%Sales to external customers: ¥2.66B ↗¥16.57M ↗0.6%
Pharmaceuticals¥2.48B ↗7.6%7.6%Sales to external customers: ¥2.47B ↗¥230.77M ↗9.3%
Food Service¥2.41B ↗7.2%7.2%Sales to external customers: ¥2.36B ↗−¥74.87M ↗-3.1%

All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended August 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

JGAAP · Consolidated
  1. FY202068.5¥22.37B
  2. FY202170.4¥23B
  3. FY202278.3¥25.58B
  4. FY202392.4¥30.19B
  5. FY2024100.0¥32.66B

Company operating profit

JGAAP · Consolidated
  1. FY202093.2¥2.25B
  2. FY202142.0¥1.01B
  3. FY202267.9¥1.64B
  4. FY202379.5¥1.92B
  5. FY2024100.0¥2.41B

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

Reported Sales by business over time

Reported Sales by business over time

Fiscal yearFY2020FY2021FY2022FY2023FY2024
Healthcare¥17.43B¥15.14B¥15.25B¥18.2B¥19.04B
Pharmaceuticals¥1.57B¥1.78B¥2.09B¥2.31B¥2.48B
Department Store Business¥3.21B¥4.7B¥5.2B¥4.95B¥4.62B
Food Service¥157.55M¥920.51M¥1.48B¥2.18B¥2.41B
Real estate and construction———¥1.95B¥2.71B

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth90
    Peer-position scoreFY2024
  • Profitability78
    Peer-position scoreFY2024
  • Business concentration—
    No comparable data
  • Business change93
    Peer-position scoreFY2020→FY2024
  • Cash generation47
    Peer-position scoreFY2024
  • Growth persistence79
    Peer-position scoreFY2020→FY2021, FY2021→FY2022, FY2022→FY2023, FY2023→FY2024

Next

Ask about this company

Source

Public filing

FY2024 · fiscal year ended August 2025

The source document may be in Japanese.

Filing ID: S100X6W8

View original filing ↗

根拠となる資料